TP53 and gastric cancer: In TP53-mutant gastric cancer cells, a strategy utilizing the KDM4C (lysine-specific demethylase 4C) inhibitor QC6352 to induce senescence (Step 1) followed by elimination with the senolytic SSK1 (Step 2) showed significant efficacy [26].